Skip to main content
SpringerLink
Log in

Letter to the Editor

  • Letter to the Editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Aapro M (2002) 5-HT3 receptor antagonists: are they all the same? Cancer Today [Suppl 1]:2–15

  2. Blower P (2003) Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer 11:93–100

    PubMed  Google Scholar 

  3. Corrigan BW, Nicholls B, Thakrar B, et al. (1999). Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos 27:110–112

    CAS  PubMed  Google Scholar 

  4. GlaxoSmithKline (2003, 2002) Zofran (ondansetron hydrochloride) oral and injection. Prescribing information/summary of product characteristics

  5. Gregory RE, Ettinger DS (1998) 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 55:173–189

    CAS  PubMed  Google Scholar 

  6. Keefe DL (2002) The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: is there cause for concern. Oncologist 7:65–72

    CAS  PubMed  Google Scholar 

  7. Perez EA, Hesketh P, Sandbach J, et al. (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754–760

    CAS  PubMed  Google Scholar 

  8. Roche Laboratories (2002, 2001) Kytríl® (granisetron hydrochloride) tablets and injection. Prescribing information/summary of product characteristics

  9. Roila F, Ballatorí E, Tonato M, et al. (1997) 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer 33:1364–1370

    Article  CAS  PubMed  Google Scholar 

  10. Watanabe H, Hasegewa A, Shínozhaki T, et al. (1995) Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmaco135:278–282

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology, Targeted Cytotoxics, Clinical Development and Medical Affairs, GlaxoSmithKline, 1250 Collegeville Road, PO Box 5089, Collegeville, Pennsylvania, 19426-0989, USA

    Mark Russo

Authors
  1. Mark Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Russo, M. Letter to the Editor. Support Care Cancer 12, 64–65 (2004). https://doi.org/10.1007/s00520-003-0545-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-003-0545-6

Keywords

Search

Navigation